Article Abstract

Hunting hidden pieces of signaling pathways in hepatocellular carcinoma

Authors: Mari Masuda


Advanced hepatocellular carcinoma (HCC) has a poor prognosis with limited treatment options. During the last decade, sorafenib, a multi-tyrosine kinase inhibitor (TKI), has been the only available systemic agent for first-line treatment of unresectable HCC (1). Recently, another multi-TKI, lenvatinib, was added to the list of first-line treatment alternatives based on the results of the phase III RREFLECT trial.